Hepatocellular Carcinoma

CD40L Gene Therapy Eradicated Tumors In Rats

Published in Gene Therapy Weekly, September 6th, 2001

by Deborah W. Heinrich, PhD, staff medical writer - CD40L gene therapy stimulated antitumor immunity followed by complete tumor regression in rats with established hepatocellular carcinomas, according to scientists in Spain.

V. Schmitz and coworkers at the University of Navarra in Pamplona explained that "unresectable hepatocellular carcinoma (HCC) lacks effective therapy and entails very poor prognosis." In an attempt to improve the prognosis, they developed a method to enhance antitumor immunity by overexpressing the T cell costimulatory molecule CD40 ligand (CD40L).

In vitro, adenovirus-mediated transfection of rat HCC cells resulted in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-09-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry